2023 World Conference on Lung Cancer (Posters)-EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases

EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases - PDF(Slides)

Back to course

Pdf Summary

In this study, the researchers present a case of a 72-year-old woman with non-small cell lung cancer (NSCLC) that had brain and leptomeningeal metastases. Despite undergoing treatment with first and third-generation TKIs, the patient developed resistance and experienced disease progression. The patient was found to have a T790M-negative mutation and there is currently no established therapeutic option for patients with this mutation. <br /><br />The researchers switched the patient to high dose Aumolertinib, a third-generation EGFR-TKI with good CNS penetration, and observed a durable response. The patient achieved a partial response to Aumolertinib with a progression-free survival of over 9 months. The treatment also provided significant relief from leptomeningeal metastases symptoms and resulted in shrinkage of brain lesions. No adverse events were reported and the survival benefit was sustained. <br /><br />This case demonstrates the safety and efficacy of high dose Aumolertinib in T790M-negative EGFR-mutant NSCLC with brain and leptomeningeal metastases after resistance to first and third-generation TKI treatments. The study suggests that Aumolertinib may be a practical strategy for rescuing targeted therapy in this patient population. <br /><br />The researchers acknowledge the study participants, their families, and caregivers, as well as the study team members and all staff involved in the trial.

Asset Subtitle

Yi-Bin Li

Meta Tag

Speaker Yi-Bin Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

non-small cell lung cancer

NSCLC

brain metastases

leptomeningeal metastases

TKIs

T790M-negative mutation

therapeutic option

Aumolertinib

EGFR-TKI

durable response